STA363 active ingredient is (S)-lactic acid mixed with a contrast agent, Iohexol and water for injection. Lactic acid is a well-known, endogenous, safe, and stable substance. Shelf life is estimated at least 36 months at room temperature. Working with lactic acid ensures no challenges in manufacturing or commercial supply.
Stayble utilizes two different modes of action of STA363 to be able to treat degenerative disc disease and disc herniation.
STA363 A DISEASE MODIFYING SINGLE TREATMENT
The STA363 treatment is a world unique, patented innovation capable of alleviating the pain of patient’s suffering from herniated discs (LDH).
Instead of costly and time-consuming procedures, such as spinal fusions or long-term physiotherapy, STA363 is administered as a one-time injection.
Removing the root cause of the pain
Both indications are single injection treatments tackling the root cause of the problem, and is expected to remain effective over a lifetime, requiring minimal rehabilitation. As such, it is anticipated to decrease the number of people on sick leave, reduce the usage of painkillers, and substantially increase the patients’ quality of life.
Making pain treatment available – for everyone
Stayble´s treatment is intended for patients suffering from leg pain thought to be caused by disc herniation. Our main aim is to help people who do not respond adequately to conservative treatment. Our treatment is much less time-consuming than conservative therapies and an experienced radiologist or spine surgeon can perform it in less than an hour.
Andreas has during the last 7 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a Master’s in economics and Venture Creation from Chalmers University of Technology.
- +46 (0)730 808 397
Anders has broad experience in drug discovery and development from AstraZeneca with a wide international network, and experience from start-ups and spin-outs, one of which he co-founded. He has acted internationally as a consultant for both large pharma companies and biotechs. Anders has an extensive experience in managing both preclinical and clinical drug development projects.
Jarkko Kalliomäki is a specialist physician in rehabilitation and pain management and a medical doctor in physiology. He has over ten years of experience in the pharmaceutical industry in a number of pain-related projects and works as a senior physician in rehabilitation medicine and pain management at, among others, Lunds Universitetssjukhus Sophiahemmet and Capio S:t Göran’s hospital, Stockholm.
Thomas has an extensive experience from the life science sector during the last 20 years. He has been CFO at Arexis (merged with Biovitrum), worked actively as business controller in Albireo (AstraZeneca spin-off now listed on Nasdaq main list) and previously CFO at Integrum (Listed on First North (SE)).
Board of directors
Ulf is a trained pharmacist with over 35 years of experience from the pharmaceutical industry. Ulf has been active in research, development and marketing of both pharmaceuticals and diagnostics with many years of experience in handling industrial collaborations, financial issues and contacts with regulatory authorities in both Europe and the United States. Among previous positions, the position as CEO of the oncology company Aprea and OxyPharma are noticeable. Ulf has previously held a number of senior positions within Pharmacia. Ulf currently works as a consultant and is currently chairman of the board of Lipum AB and a board member of TikoMed AB and MedicaNatumin AB.
JANE BUUS LAURSEN
Jane Buus Laursen is Corporate Vice President and head of Novo Nordisk’s Late Stage & Commercial Business Development. Before that, she spent 15 years at AstraZeneca where she completed a large number of deals with biotechs, pharma and academia spanning from early stage to late stage business transactions across all of AstraZeneca’s strategic areas. Her CV includes licensing deals, M&As, commercial partnerships and divestments of late stage clinical and on-market assets, in addition to spin-out of early stage assets.
Erik Kinnman has broad leadership experience and expertise from various assignments in the life science sector and many years of experience from leading positions in pharmaceutical companies such as AstraZeneca and Sobi. Erik's expertise and experience encompass clinical development, business strategy, business development and investor relations, and he also has experience from the finance sector. He holds an Executive MBA degree from Stockholm School of Economics and extensive research qualifications from the Karolinska Institute where he received his PhD degree and Associate Professorship. Erik holds an MD degree with specialist expertise in neurology and pain relief.
Gudrun is a trained pharmacist with over 35 years of experience from marketing companies in the pharmaceutical industry in global positions, including Organon, ICI-Pharma, Zeneca and AstraZeneca, as well as consulting in smaller biotech companies. Gudrun has been active in all aspects of drug development, which has included the management of a number of global projects from pre-clinic to phase-3. She has worked in the approval phase as well as during launch and in several different disease areas.
Gunnar is Investment Director at InnovationsKapital, a venture capital company focusing on innovative companies in the early stages from the Nordic region. Gunnar is responsible for their investments in Health / Medical and Life Sciences and has made a total of 18 investments in the area. He is currently a member of the boards of Besedo, PBM, Scienta Scientific and Chalmers Innovation and chairman of Chalmers Industriteknik. Gunnar has a degree in chemical engineering from Chalmers.
Björn Strömqvist, MD, PhD, is Professor of Orthopedic Surgery at the Spine Section, Department of Orthopedics, Skåne University Hospital, Sweden. His research interests focus mainly on spinal stability, outcome studies, tumours, fractures and minimally invasive lumbar spine surgery. Björn is author of >250 publications in peer-reviewed journals. He is Preceptor of the Swedish National Register of Spine Surgery, Swespine, and member of the Steering Group. He is also a member of several national and international associations in the field of lumbar back surgery . He has received numerous awards such as the Acromed Award, the Volvo Award and Eurospine Best Paper Award.
Dr Daisuke Sakai is an Associate Professor in the Department of Orthopaedic Surgery at Tokai University School of Medicine in Kanagawa, Japan. Sakai’s main clinical interest is the pathology of degenerative spinal disease and treatment of spinal deformities. He is also the head of the Spinal Disc Disease Research Unit, which focuses primarily on the cellular and molecular biology of the spinal disc. The unit also evaluates different types of new treatments, including those based on stem cells. He has led several clinical trials in degenerative disc disease and received the 2014 Research Achievement Award from the Japanese Orthopaedic Association and the 2018 Berton Rahn Research Award from the AO Foundation.
Douglas Beall, MD, is Chief of Interventional Spine Services and Chief of Radiology Services at Clinical Radiology of Oklahoma, Oklahoma City, OK, USA. In addition to expertise in Musculoskeletal Imaging and Interventional Spine Care, Dr. Beall is a Diplomate of the American Academy of Pain Management, a Fellow of the Society of Interventional Radiology and a Fellow of Interventional Pain Practice. He is actively involved in teaching and research, publishing more than 250 articles in peer-reviewed journals, 6 textbooks, 60 textbook chapters, and more than 1000 invited lectures and scientific presentations. Dr. Beall has been involved in several clinical trials on new interventions in discogenic low back pain.
Hans Jörg Meisel,
Hans Jörg Meisel, MD, PhD, Prof., is Director of the Center of Neurosciences and the Chair of the Department of Neurosurgery at the BG-Clinic Bergmannstrost Halle, Berlin, Germany. Prof. Meisel is an inventor and designer of spinal implants, and developed the first biological disc repair transplantation system with autologus chondrocytes in 1995. He has since then expanded his clinical trial expertise by initiating the EU Project ‘RESPINE’ together with colleagues in 2016.